The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease

被引：0
|
作者：
Macaluso, F. S. [1 ]
Grova, M. [1 ]
Saladino, M. [2 ]
Demarzo, M. G. [3 ]
Privitera, A. C. [4 ]
Giangreco, E. [5 ]
Garufi, S. [6 ]
Renna, S. [1 ]
Casa, A. [1 ]
Ventimiglia, M. [7 ]
Cappello, M. [2 ]
Fries, W.
Orlando, A. [1 ]
机构：
[1] Osped Riuniti Villa Sofia Cervello, IBD Unit, Palermo, Italy
[2] Univ Palermo, Gastroenterol & Hepatol Sect Promise, Palermo, Italy
[3] Univ Messina, IBD Unit, Messina, Italy
[4] Cannizzaro Hosp, IBD Unit, Catania, Italy
[5] Guzzardi Hosp, Gastroenterol Unit, Vittoria, Italy
[6] ARNAS Garibaldi, Gastroenterol Unit, Catania, Italy
[7] Italian Minist Hlth, Directorate Gen Med Device & Pharmaceut Serv, Rome, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P345
引用
收藏
页码：I359 / I359
页数：1
相关论文
共 50 条
  • [1] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [2] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [3] The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn?s disease
    Macaluso, Fabio Salvatore
    Grova, Mauro
    Saladino, Marica
    Cappello, Maria
    Demarzo, Maria Giulia
    Privitera, Antonino Carlo
    Giangreco, Emiliano
    Garufi, Serena
    Renna, Sara
    Casa, Angelo
    Ventimiglia, Marco
    Fries, Walter
    Orlando, Ambrogio
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (04) : 471 - 477
  • [4] A MARKOV MODEL EVALUATING THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO VEDOLIZUMAB FOR PATIENT'S WITH CROHN'S DISEASE AS THIRD-LINE THERAPY
    Schneider, Yecheskel
    Saumoy, Monica
    Cohen-Mekelburg, Shirley A.
    Gold, Stephanie
    Scherl, Ellen
    Steinlauf, Adam F.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S589 - S589
  • [5] Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children
    Howard, Gadi
    Weiner, Dror
    Bar-Or, Itzhak
    Levine, Arie
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (04) : 372 - 374
  • [6] Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn?s disease
    Melotti, Laura
    Dussias, Nikolas Konstantine
    Salice, Marco
    Calabrese, Carlo
    Baldoni, Monia
    Scaioli, Eleonora
    Belluzzi, Andrea
    Mazzotta, Elena
    Gionchetti, Paolo
    Rizzello, Fernando
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 230 - 234
  • [7] Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn's disease
    Dussias, N.
    Rizzello, F.
    Calabrese, C.
    Passino, A. Sanna
    Melotti, L.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S528 - S528
  • [8] Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease
    Huff-Hardy, Kayci
    Bedair, Mai
    Vazquez, Rebecca
    Burstein, Ezra
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) : E49 - E49
  • [9] COMPARATIVE SAFETY AND EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY CROHN'S DISEASE PATIENTS
    Gebeyehu, Gerum Gashaw
    Fiske, Joseph
    Liu, Eleanor
    Limdi, Jimmy
    Davies, Mike
    Baig, Daniyal
    Liaros, Angela
    Gaba, Waqas
    Smith, Philip
    Subramanian, Sreedhar
    [J]. GUT, 2022, 71 : A47 - A48
  • [10] The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (10) : 948 - 957
12345